CVS Health (NYSE:CVS – Get Free Report) had its price target increased by stock analysts at Leerink Partners from $51.00 to $55.00 in a research report issued to clients and investors on Tuesday. The brokerage currently has a “market perform” rating on the pharmacy operator’s stock. Leerink Partners’ price target indicates a potential downside of 0.02% from the stock’s current price.
CVS has been the topic of several other research reports. Royal Bank of Canada dropped their target price on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Truist Financial cut their target price on CVS Health from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. StockNews.com cut shares of CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Mizuho reduced their price objective on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, TD Cowen raised their target price on shares of CVS Health from $73.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, November 25th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.
Check Out Our Latest Research Report on CVS Health
CVS Health Stock Up 1.3 %
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. Assetmark Inc. lifted its holdings in shares of CVS Health by 9.7% in the 3rd quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock valued at $25,781,000 after buying an additional 36,132 shares during the period. TD Private Client Wealth LLC lifted its holdings in CVS Health by 28.7% in the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock valued at $2,951,000 after acquiring an additional 10,465 shares during the period. Cullinan Associates Inc. boosted its position in CVS Health by 43.8% in the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock worth $7,125,000 after purchasing an additional 37,395 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of CVS Health by 4.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after purchasing an additional 66,244 shares during the period. Finally, Sompo Asset Management Co. Ltd. lifted its stake in shares of CVS Health by 8.4% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator’s stock valued at $8,459,000 after purchasing an additional 10,453 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.
About CVS Health
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
- Five stocks we like better than CVS Health
- Investing in Travel Stocks Benefits
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Consumer Staples Stocks, Explained
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- 5 discounted opportunities for dividend growth investors
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.